{
  "docId": "019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "docSlug": "4047dd7a7e0f28ca31128b58ef648c55",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 39,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": "Includes patient photos and disease-specific context.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b48b-74ad-8fcb-69ba4c0494fb/32",
  "deckHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "deckJsonHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb.json",
  "deckAnchorHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.38,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "gMG = generalised myasthenia gravis; NMOSD = neuromyelitis optica spectrum disorder; HPP = hypophosphatasia. 1. Q3 2021 revenues from date of acquisition closing, 21 July 2021 through 30 September 2021; pro-forma growth rates calculated by comparing post-acquisition revenues with the corresponding prior year Q3 revenues adjusted pro-rata to match the post-acquisition period.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3af9e49c-7b37-42d2-a081-2a57387675d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 1,
        "w": 0.35,
        "x": 0,
        "y": 0
      },
      "kind": "image",
      "text": "Patient photos",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bd1baea-a234-446d-8c96-6d829ccfbbb7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.18,
        "x": 0.79,
        "y": 0.25
      },
      "kind": "list",
      "text": "Strensiq: Global $159m (+8%), US (+6%), EU (+5%), EM (+75%), ERoW (+11%). Strong underlying volume growth in US.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28058c54-5672-4a15-99a7-71d90fc78458",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.57,
        "y": 0.25
      },
      "kind": "list",
      "text": "Ultomiris: Global $297m (+31%), US (+25%), EU (+77%), EM (n/m), ERoW (+5%). Performance driven by strong conversion from Soliris, and 14 new country launches this year.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58f0a051-e855-4951-a264-4b77247c6b71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "Soliris: Global $798m (-2%), US (+4%), EU (-3%), EM (-40%), ERoW (+10%). Strong volume growth in Neurology, offset by successful conversion to Ultomiris and prior year EM tender market order timing.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4c12d9a-f7c5-436c-af73-e9e400febbe5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.58,
        "x": 0.38,
        "y": 0.06
      },
      "kind": "title",
      "text": "Rare Disease Q3 2021 performance highlights leading C5 franchise",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dde4e7ce-9a80-4c1c-b89b-7ac709d39d7f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b9805dcd-a59e-4c5b-8397-e47d307f9a94",
      "evidence": "The slide presents information in a list format, with bullet points highlighting performance highlights for Rare Disease Q3 2021.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}